Ensysce Biosciences 

Ensysce Biosciences, Inc. is a pharmaceutical firm in the clinical development stage, specializing in the creation of prescription medications. Their primary focus is to address severe pain relief while simultaneously mitigating the risks associated with opioid misuse, abuse, and overdose across the United States. The company's innovative approach is built upon two proprietary technological platforms: the Trypsin Activated Abuse Protection (TAAP) platform, which renders opioid prodrugs abuse-resistant, and the Multi-Pill Abuse Resistance (MPAR) platform, designed to offer overdose protection against excessive ingestion. Key pipeline candidates include PF614, a TAAP-enabled oxycodone prodrug currently being developed for the management of acute and chronic pain. They are also advancing PF614-MPAR, which combines PF614 with nafamostat, specifically engineered to provide overdose protection. Furthermore, Ensysce is exploring oral and inhaled formulations of nafamostat for potential applications beyond pain management, including the treatment of coronaviral infections and other pulmonary conditions such as cystic fibrosis. Beyond opioids, the company's portfolio extends to include PF8001 and PF8026, which are extended- and immediate-release amphetamine prodrugs aimed at preventing the abuse of ADHD medications. Ensysce Biosciences, Inc. maintains its headquarters in La Jolla, California.